0001209191-20-045105.txt : 20200805 0001209191-20-045105.hdr.sgml : 20200805 20200805162422 ACCESSION NUMBER: 0001209191-20-045105 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silva Paul M CENTRAL INDEX KEY: 0001446372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 201077689 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001446372 Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP & Controller Common Stock 2020-08-03 4 M 0 809 86.52 A 15741 D Common Stock 2020-08-03 4 S 0 51 276.00 D 15690 D Common Stock 2020-08-03 4 S 0 310 277.73 D 15380 D Common Stock 2020-08-03 4 S 0 429 278.92 D 14951 D Common Stock 2020-08-03 4 S 0 19 279.61 D 14932 D Common Stock 169 I 401(k) Stock Option (Right to Buy) 86.52 2020-08-03 4 M 0 809 0.00 D 2027-02-02 Common Stock 809 1618 D Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $277.73 (range $277.25 to $278.22). Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $278.92 (range $278.47 to $279.38). The option vests in 16 quarterly installments from 02/03/2017. /s/ Sabrina Yohai, Attorney-in-Fact 2020-08-05